Latest News about Fda
Recent news which mentions Fda
Cannabis For Pain Relief: Scientists Develop New Compound Without Mind-Altering Effects — Alternative To Opioids?
March 06, 2025
From Benzinga
FDA Approves ARS Pharmaceuticals' Lower Dose Neffy Nasal Spray For Emergency Allergy Treatment
March 06, 2025
From Benzinga
FDA Places Clinical Hold On BioNTech's Early-Phase Trial For RNA-Based Malaria Vaccine
March 05, 2025
From Benzinga
Capricor Therapeutics Cell Therapy Goes Under Priority FDA Review For Duchenne Associated-Heart Condition
March 04, 2025
From Benzinga
China-Based Biotech BeiGene Scores FDA Approval For Tevimbra/Chemo Combo For Untreated Patients With Esophageal Cancer
March 04, 2025
From Benzinga
From Benzinga
Amgen-AstraZeneca Partnered Asthma Drug Shows Rapid And Sustained Effect In Chronic Rhinosinusitis
March 03, 2025
From Benzinga
Novo Nordisk's Ozempic And Wegovy No Longer on FDA Shortage List, Faces Lawsuit Over Decision
February 26, 2025
From Benzinga
Bristol Myers Colorectal Cancer Treatment Goes Under Priority FDA Review
February 24, 2025
From Benzinga
FDA Approves Medtronic's Adaptive Deep Brain Stimulation System For Parkinson's Patients
February 24, 2025
From Benzinga
FDA Clears Entrada Therapeutics' Early-Stage For Potential Treatment Of Duchenne Muscular Dystrophy
February 24, 2025
From Benzinga
FDA Rejects Invivyd's Request To Expand Emergency Authorization For Preventive COVID-19 Antibody For Immunocompromised Patients
February 24, 2025
From Benzinga
FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery
February 24, 2025
From Benzinga
Penny Stock Co-Diagnostics Withdraws FDA Application For COVID-19 Test, Plans To Submit Enhanced Version
February 24, 2025
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.